IL4 / IL13 receptor molecules for veterinary use
The IL13R/IL4R continuous polypeptides address the challenge of reducing IL4 and IL13 signaling in companion animals by binding to these cytokines, effectively alleviating allergic diseases such as atopic dermatitis and asthma.
Patent Information
- Application Number
- JP2019556941
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2017-04-21
- Filing Date
- 2018-04-20
- Publication Date
- 2025-04-07
- Estimated Expiration
- 2038-04-20
AI Technical Summary
Companion animals such as dogs, cats, and horses suffer from allergic diseases like atopic dermatitis and asthma, which are induced by interleukin 4 (IL4) and interleukin 13 (IL13). There is a need for methods and compounds that can specifically bind to these cytokines in companion animals to reduce their signaling activity and alleviate associated clinical signs.
The development of continuous polypeptides comprising the extracellular domains of IL13R and IL4R derived from companion animal species. These polypeptides, such as IL13R-L1-IL4R-L2-FP or IL4R-L1-IL13R-L2-FP, are designed to bind to IL4 and/or IL13, thereby reducing their signaling activity in companion animals.
The IL13R/IL4R continuous polypeptides effectively bind to IL4 and IL13 with high affinity, reducing their signaling activity in companion animals. This leads to a decrease in the clinical signs associated with allergic diseases such as atopic dermatitis and asthma, providing a therapeutic benefit for companion animals.